Download PDF
Aktuelle Rheumatologie 2011; 36(06): 378-383
DOI: 10.1055/s-0031-1283172
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

„Gender Aspects“ bei Vaskulitiden und der Polymyalgia rheumatica

Gender Aspects in Vasculitides and Polymyalgia Rheumatica
E. Reinhold-Keller
1   Internistisch-rheumatologische Gemeinschaftspraxis, Hamburg
› Author Affiliations
Further Information

Publication History

Publication Date:
23 September 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bislang gibt es nur wenige Untersuchungen zu geschlechtsspezifischen Aspekten bei Vaskulitiden. In ihrem Vorkommen zeigen die Riesenzellarteriitis (RZA) und die Polymyalgia rheumatica (PMR) eine eindeutige Präferenz des weiblichen Geschlechts. Inzidenz und Prävalenz der RZA und PMR sind bei Frauen ab dem 50. Lebensjahr ca. 3–5 fach höher als in der männlichen Vergleichspopulation. Unterschiede gibt es möglicherweise auch im Krankheitsverlauf der PMR. Frauen mit einer PMR haben eine längere Krankheitsdauer, häufiger Rezidive und benötigen eine höhere kumulative Prednisolon-Dosis als Männer. ANCA-assoziierte Vaskulitiden (AAV) kommen bei Männern und Frauen gleich häufig vor. Während sich das Gesamt-Outcome für Patienten mit AAV in den letzten Jahrzehnten deutlich verbessert hat mit vergleichbarer Mortalität bei jüngeren AAV-Patientinnen mit der Normalbevölkerung, besteht für Männer mit einer Wegenerschen Granulomatose nach wie vor eine Übersterblichkeit, die bei jüngeren Männern sogar das fast 9-fache im Vergleich zur Normalbevölkerung beträgt. Bei den sozioökonomischen Krankheitsfolgen gibt es deutliche Nachteile für jüngere Frauen mit einer Vaskulitis, sie haben ein fast 3-fach höheres Risiko für den Verlust des Arbeitsplatzes als Männer.

Abstract

Little data exist on gender differences in vasculitides. Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have a marked predominance in women. The incidence and prevalence rates of the GCA and PMR are 3- to 5-fold higher in women aged 50 years and older compared to the older male population. The course of PMR is more severe in women. Women with PMR have longer disease duration vs. male patients. Women are treated with a higher cumulative dosage of prednisone and suffer more frequently from relapses, leading to a higher number of therapy-related side effects. In the epidemiology of ANCA-associated vasculitides no differences were found between men and women. Whereas the overall outcome of ANCA-associated vasculitides has improved dramatically, young males have a considerably higher standardised mortality rate (nearly 9-fold) compared with the general population (and young females). Considering also the effects of vasculitides on work disability, younger employed women with Wegener’s granulomatosis at diagnose had a nearly 3-fold higher risk of losing their jobs compared with men.

Schlüsselwörter

Vaskulitis - Riesenzellarteriitis - Polymyalgia rheumatica - ANCA-assoziierte Vaskulitiden - Outcome

Key words

vasculitis - giant cell arteritis - polymyalgia rheumatica - ANCA-associated vasculitis - outcome
 

  • Literatur

  • 1 Bird HA, Esselinckx W, Dixon AS et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-439
    CrossrefPubMedGoogle Scholar
  • 2 Fries JF, Hunder GG, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-1136
    PubMedGoogle Scholar
  • 3 Boesen P, Sörensen SF. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica in a Danish County. Arthritis Rheum 1987; 30: 294-299
    CrossrefPubMedGoogle Scholar
  • 4 Salvarani C, Maccioni P, Zizzi F et al. Epidemiologic and immunogenetic aspects of polymyalgia reumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-356
    CrossrefPubMedGoogle Scholar
  • 5 Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000; 27: 2624-2627
    PubMedGoogle Scholar
  • 6 Kermani TA, Schäfer VS, Crowson CS et al. Increase in age at onset of giant cell arteritis: a population based study. Ann Rheum Dis 2010; 69: 780-781
    CrossrefPubMedGoogle Scholar
  • 7 Reinhold-Keller E, Buckert F, Herlyn K et al. Verdopplung der Prävalenz der RZA und AAV zwischen 1994 und 2006. DGIM 2010; (Poster)
    PubMedGoogle Scholar
  • 8 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R et al. Stable incidence of primary systemic vasculitides over 5 years: Results from the German vasculitis register. Arthritis Care Res 2005; 53: 93-99
    CrossrefPubMedGoogle Scholar
  • 9 Koldingsnes W, Nossent H. Epidemiology of Wegener’s granulomatosis in Northern Norway. Arthritis Rheum 2000; 43: 2481-2487
    CrossrefPubMedGoogle Scholar
  • 10 Knight A, Ekbom A, Brandt L et al. Increasing incidence of Wegener’s granulomatosis in Sweden, 1975-2001. J Rheumatol 2006; 33: 2060-2063
    PubMedGoogle Scholar
  • 11 Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Concensus Conference Defintions. Arthritis Rheum 2003; 49: 388-393
    CrossrefPubMedGoogle Scholar
  • 12 Cotch MF, Hoffman GS, Yerg DE et al. The epidemiology of Wegener’s granulomatosis. Arthritis Rheum 1996; 39: 87-92
    CrossrefPubMedGoogle Scholar
  • 13 Takala JH, Kautiaienen H, Malmberg H et al. Incidence of Wegener’s granulomatosis in Finland 1981-2000. Clin Exp Rheumatol 2008; 26 (Suppl. 49) S81-S85
    PubMedGoogle Scholar
  • 14 Herlyn K, Hellmich B, Gross WL et al. Stabile Inzidenz systemischer Vaskulitiden in Schleswig-Holstein. Dtsch Arztebl 2008; 105: 355-361
    PubMedGoogle Scholar
  • 15 Watts RA, Al-Taiar A, Scott DGI et al. Prevalence and incidence of Wegener’s granulomatosis in the UK General Practice Research Database. Arthritis Rheum 2009; 61: 1412-1416
    CrossrefPubMedGoogle Scholar
  • 16 Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008; 38: 816-823
    CrossrefPubMedGoogle Scholar
  • 17 Mahr A, Guillevin L, Poissonnet M et al. Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis and Churg Strauss syndrome in a Frenche urban multiethnic population in 2000, a capture-recapture estimate. Arthritis Care & Res 2004; 51: 92-99
    PubMedGoogle Scholar
  • 18 Mohammad AJ, Jacobsson LTH, Mahr AD et al. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007; 46: 1329-1337
    CrossrefPubMedGoogle Scholar
  • 19 Reinhold-Keller E, Zeidler A, Gutfleisch J et al. Giant cell arteritis is more prevalent in urban than in rural population: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumtology 2000; 39: 1396-1402
    PubMedGoogle Scholar
  • 20 Narvaez J, Nolla-Sole JM, Clavaguera MT. Longterm therapy in polymyalgia rheumatica: effect for coexistent temporal arteritis. J Rheumatol 1999; 26: 1945-1952
    PubMedGoogle Scholar
  • 21 Cimmino MA, Parodi M, Caporali R et al. Is the course of steroid-treated polymyalgia rheumatica more severe in women?. Ann NY Acad Sci 2006; 1069: 315-321
    CrossrefPubMedGoogle Scholar
  • 22 Salvarani C, Cantini F, Niccoll L et al. Acut-phase reactans and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective follow-up study. Arthritis Rheum 2005; 53: 33-38
    CrossrefPubMedGoogle Scholar
  • 23 Tanaka H, Akama H, Ichikawa Y. Glucocorticoid receptors in normal leukocytes: effects of age, gender, season, and plasma cortisol concentration. Clin Chem 1991; 37: 1715-1719
    PubMedGoogle Scholar
  • 24 Hoffman GS, Kerr GS, Leavitt RY et al. Wegeners granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
    CrossrefPubMedGoogle Scholar
  • 25 Reinhold-Keller E, Beuge N, Latza U et al. An interdiciplinary approach to the care of patients with Wegeners granulomatosis. Arthritis Rheum 2000; 43: 1021-1032
    CrossrefPubMedGoogle Scholar
  • 26 Holle J, Gross WL, Latza U et al. Improved outcome of 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decadeds. Arthritis Rheum 2011; 63: 257-266
    CrossrefPubMedGoogle Scholar
  • 27 De Groot K, Rasmussen N, Bacon PA et al. for the European Vasculitis Study Group (EVAS). Randomized trial of cyclophosphamide vs. Methotrexate for induction of remission in early systemic ANCA-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469
    CrossrefPubMedGoogle Scholar
  • 28 Jayne DRW, Rasmussen N, Andrassy K et al. for the European Vasculitis Study Group (EUVAS). A randomized trial of maintenance therapy for vasculiits associated with antineutrophil cytoplasmic antiboides. N Engl J Med 2003; 349: 36-44
    CrossrefPubMedGoogle Scholar
  • 29 Jayne DRW, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
    CrossrefPubMedGoogle Scholar
  • 30 Mukhtyar C, Guillevin L, Cid MC et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
    CrossrefPubMedGoogle Scholar
  • 31 Holle JU, Gross WL, Holl-Ulrich K et al. Prospective long-term follow-up of patients with localized Wegener’s granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis 2010; 69: 1934-1939
    CrossrefPubMedGoogle Scholar
  • 32 Matteson El, Gokd KN, Bloch DA. Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatolgy Wegener’s granulomatosis classification cohort. Am J Med 1996; 101: 129-134
    CrossrefPubMedGoogle Scholar
  • 33 Lane SE, Watts RA, Shepstone L et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98: 97-111
    CrossrefPubMedGoogle Scholar
  • 34 Aasarod K, Iversen BM, Hammerstrom J et al. Wegener‘s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 611-618
    CrossrefPubMedGoogle Scholar
  • 35 Little MA, Nightingale P, Verburgh CA et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-1043
    CrossrefPubMedGoogle Scholar
  • 36 Eriksson P, Jacobsson L, Lindell A et al. Improved outcome in Wegener’s granulomatosis and microscopic polyangiitis. A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009; 265: 496-506
    CrossrefPubMedGoogle Scholar
  • 37 Stratta P, Maruccio C, Campo A et al. Improvement in relative survival of patients with vasculitis: Study of 101 cases compared to the general population. Int J Immunopathol Pharmacol 2008; 21: 631-642
    PubMedGoogle Scholar
  • 38 Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (BVAS version 3). Ann Rheum Dis 2009; 68: 1827-1832
    CrossrefPubMedGoogle Scholar
  • 39 De Groot K, Gross WL, Herlyn K et al. Development and validation of a Disease Extent Index for Wegener’s granulomatosis. Clin Nephrol 2001; 55: 31-38
    PubMedGoogle Scholar
  • 40 Exley AR, Bacon RP, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-380
    CrossrefPubMedGoogle Scholar
  • 41 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R et al. Effect of Wegener’s granulomatosis on work disabilitiy, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum 2002; 47: 320-325
    CrossrefPubMedGoogle Scholar
  • 42 Hewlett S. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003; 30: 877-879
    PubMedGoogle Scholar
  • 43 Herlyn K, Hellmich B, Seo P et al. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res 2010; 62: 1639-1645
    CrossrefPubMedGoogle Scholar